Small US firm VistaGen Therapeutics Inc. is hoping that fresh impetus in the depression market will help propel its candidates towards the market, despite pipeline setbacks.
After around 30 years on pause, the pipeline for depression treatments started to flow again in 2019, with the arrival...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?